Prognoses and complications of patients with hematological malignancies after haploidentical or siblingidentical donor stem cell transplantations
10.3760/cma.j.issn.0254-1785.2016.11.007
- VernacularTitle:单倍体与同胞全相合造血干细胞移植治疗恶性血液病的疗效与并发症分析
- Author:
Long SU
;
Xiaoliang LIU
;
Yehui TAN
;
Yangzhi ZHAO
;
Yu LIU
;
Qiuju LIU
;
Ping YU
;
Naifei CHEN
;
Wei HAN
;
Mengmeng LIU
;
Jingnan SUN
;
Sujun GAO
;
Wei LI
- Keywords:
Hematological malignancies;
Hematopoietic stem cell transplantation;
Outcomes;
Complications
- From:
Chinese Journal of Organ Transplantation
2016;37(11):672-676
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the long-term outcomes and complications of patients with hematological malignancies (HM) after haploidentical donor transplantation (HDT) or siblingidentical donor transplantation (SDT).Methods From June,2011 to July,2016,89 patients with HM receiving allo-HSCT were retrospectively analyzed,including 57 patients undergoing HDT and 32 cases undergoing SDT.Results The median time to achieve neutrophil engraftment was 2 days shorter after HDT than SDT,whereas that of platelet engraftment was 3 days longer after HDT than SDT.The cumulative incidence for 3 to 4 grade acute graft-versus-host disease (GVHD) was not obviously different between HDT and SDT (8.77％ versus 12.5％ respectively;x2 =0.313,P =0.576).The cumulative incidence for chronic GVHD was not significantly different between HDT and SDT (45.6％ versus 37.5％;~ =0.551,P =0.458).Cytomegalovirus (CMV) reactivity was significantly higher in patients after HDT (77.19％) than those after SDT (21.88％) (x2 =25.633,P＜0.001).The occurrence of hemorrhagic cystitis was also obviously higher in patients after HDT (26.32％)than those after SDT (3.85％) (x2 =5.340,P =0.021).The 1-,2-,and 3-year relapse-free survival rate of patients receiving HDT and SDT was 63.9％,55.4％,44.3％ and 71.2％,58.3％,51.8％,respectively (P =0.541).The 1-,2-,and 3-year overall survival rate of patients receiving HDT and SDT was 75.3％,65.3％,52.3％ and 76.9％,62.9％,62.9％,respectively (P =0.777).Conclusion Considering similar incidence of severe GVHD and long-term outcomes,haploidentical donors should be recommended as a potential alternative donor source when an identical donor is lacking for patients with HM.
